PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
FDA Approves BeiGene's Tevimbra in First-Line PD-L1-Positive Esophageal Cancers
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
Cel-Sci to Initiate Phase III Trial of Immunotherapy in PD-L1-Low Head and Neck Cancer
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
Bicara Therapeutics Begins Trial of Ficerafusp Alfa, Keytruda in First-Line Head and Neck Cancer
The Phase II/III trial will include patients with PD-L1-positive tumors and who are HPV-negative.
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.